Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits
New York, Jan 7, 2026, 11:04 EST — Regular session Shares of Crinetics Pharmaceuticals rose about 16% to $53.40 on Wednesday, after the biotech priced a $350 million stock offering and detailed early U.S. launch metrics for its newly approved